JAMA
EMBARGOED FOR RELEASE: 10 A.M. (ET), MONDAY, DECEMBER 11, 2023
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
About The Study: In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction in this randomized clinical trial that included 670 adults.
Authors: Louis J. Aronne, M.D., of Weill Cornell Medicine in New York, is the corresponding author.
(doi:10.1001/jama.2023.24945)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.